The risk of acquiring hepatitis B and C in the oncology setting was historically high and predominantly related to blood product administration in the prescreening era. With the development of progressively more sophisticated testing for hepatitis B and C, breaches in infection control have played an increasingly prominent role in disease transmission. Optimizing infection control in inpatient and outpatient oncology settings is essential in preventing the health care-associated transmission of hepatitis B and C to oncology patients.
(c) 2010 Elsevier Inc. All rights reserved.